About Us

Dr Eng Chon Boon, is the director for the Tissue Repository, National University Hospital (NUH) and runs the Hospital-based Cancer Registry (HCR) at the National University Cancer Institute (NCIS) and has an adjunct position in the Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore (NUS). He is also the principal person-in-charge of tissue banks across the National University Health System (NUHS) public healthcare cluster and the lead PI for the Singapore Integrated Network of Biorepositories (SINB), an infrastructure network formed by academic tissue repositories in Singapore. He is the Singapore’s convenor for ISO//TC276 Biotechnology and in the editorial board of “Biopreservation and Biobanking” by Mary Ann Liebert.

He is a past recipient for International Society for Biological and Environmental Repositories (ISBER) special service award (2010) and had numerous voluntary responsibilities within the ISBER over the years (Councilor, Chair of the ISBER Marketing Committee, members of ISBER Finance, Nominating, Strategic Planning, Program Committee). He is also the Vice-chair of Local Organizing Committee for the 2007 ISBER Annual Meeting in Singapore.

He has numerous publications/book chapter/patent in the field of biobanking and had given talks, conducted biobanking workshops and consulted for various international biobanks over the past 15 years. For a list of biobanking activities and further info, please refer to the following:

Publications

LinkedIn profile

Tissue Repository website

Dr. Rajeev Singh, MD, MBA, is Director, Biorepository at Houston Methodist Research Institute, Houston, TX, USA. Dr. Singh is a trained pathologist, obtaining his basic medical and specialist degree in India and his MBA from USA. Dr. Singh has been a biobanker for last 15 years having worked across various positions in biobanks in Singapore and US.

Dr. Singh is an active ISBER member for last 15 years and has been involved with the Biospecimen Science, Standards and Finance committees of ISBER, currently and in the past. Dr. Singh has co-chaired sessions and led round table discussions on important biobanking issues in past ISBER meetings. Dr. Singh has been a part of the task force that reviewed the 4th edition of ISBER Best practices. Dr. Singh has delivered international talks on biobanking related topics and sits on the advisory panel for an Indian biobank. Dr. Singh has published/presented biobanking related articles and posters in various journals and conferences.

Dr. Singh’s focus areas in biobanking are biospecimen quality and donor perspectives. Dr. Singh is currently driving his biorepository towards CAP accreditation and is a certified CAP Biorepository Inspector.

Barjinder is a solicitor-advocate with nearly 30 years litigation experience at the Royal Courts of Justice in London.  He is now deep diving into issues related to ethics and compliance in the areas of health research (including clinical trials), biobanking, health data, artificial intelligence and robotics – including the application of blockchain and smart contracts.  He sits on a number of ethics committees involved in health, biobanking, and technology. Detailed bio.

Dr. Ray Perkins, PhD, is Founder and President of New Liberty Proteomics Corp., an organization whose unique mission is integration of Drug and Diagnostics development in support of Personalized (Precision) Medicine.  NLP assesses the impact of disease and drugs on fundamental molecular and cellular activity.  Areas of emphasis include development of network-based diagnostics for cancer and dementia.  Dr. Perkins earned a PhD from Vanderbilt University where he was a research fellow for the Muscular Dystrophy Association, adapting magnetic resonance technologies to assessment and diagnosis of Duchenne Muscular Dystrophy.  Recent activities include expert panelist for events such as “Medicines in the 21^st Century” recently held in Wales, and multiple publications*, each of which has been downloaded thousands of times.  In this era of the COVID pandemic Dr. Perkins is called upon in multiple capacities including evaluation of likely therapies and diagnostics.

* “Making the Case for Functional Proteomics”

“Proteases, Pivot Points in Functional Proteomics”

“COVID-19 Pandemic Surgery Guidance”

Jeanne-Hélène di Donato has been involved in biobank professionalization for almost 25 years, first as manager of the French AFM-Généthon biobank for a period of 14 years, then as a consultant for biobanks through her 3C-R Company for the past 15 years. She worked for many years on the establishment of best practices for Biological Resource Centres. For example, she was a Member of the French delegation to the OECD BRC Task Force and leader of the working group on best practice guidelines for human-derived material. She participated in the development of French law on management of collections and use of human samples for research. She is also co-author of French Standard NF S 96-900 for a biobank quality management system.

Today she is certified for her consulting activities  (helping biobanks with their logistics, quality management systems, administrative, ethical and legal development requirements) and training missions. She is also an auditor (NF S 96-900, ISO 20387, ISO 9001). She is the manager of the largest francophone biobank network (125 biobanks are members of Club 3C-R) established to promote discussion, collaboration and problem solving, In addition, she is a lecturer on Master degree for biobank managers at the Catholic University of Lyon. She is a member of the French Ethical Committee for clinical trials, and also a member of  Eurobiobank, ISBER and ESBB international biobanking networks.

Dr Betsou (PhD, HDR) is Chief Scientific Officer at IBBL. She has 25 years of experience in molecular diagnostics, disease-oriented biobanking and biospecimen research, and 15 years of experience in ISO 9001 and ISO 17025 application to biobanks. She holds 3 patents, authored of more than 100 peer-reviewed publications and teaches in several biobanking training courses across Europe. She is the chair of the ISBER Biospecimen Science Working Group and of the Proficiency Testing Advisory Group and the Luxembourg national delegate in ISO REMCO and ISO TC276.

Liam Burke Masterson is a Clinical Partnership Manager at Genuity Science. One of his current key roles is to build longstanding mutually beneficial collaborations with clinicians and academic cohort custodians. Genuity Science is a contract genomics and data-sourcing, analytics and insights organization headquartered in Boston, Massachusetts, USA with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity works in collaboration with clinicians, patients, academic researchers and global pharmaceutical companies to use the power of population genomics to discover pathways to new treatments and new diagnostics.

Liam has an M.Sc. in Project and Programme Management as well as extensive background in Biobanking having been a key member of the Qatar Biobank team from initiation stages through collaboration with Imperial College London towards biobank maturity. During this time, he gained extensive insight from biobanking experts including many of the leading international experts, including hands on experience such as disaster management, cryopreservation and transition to automaton. During this time Liam became involved with ESBB and ISBER and has continued to participate in the biobanking community. Liam spent over 7 years in the Middle East until returning to his native Ireland in 2018 to take up his current position with one of the leading genomics organisations.

CEO & Co Founder of Genobank.io, Serial Entrepreneur, +15 years experience in UNIX, Cybersecurity, Cloud Computing; +5 years experience in Blockchain & Smart Contracts.  Recently specialized in the intersection of Privacy Laws, Genomics & Bioinformatics.

Holds BS Electronics Engineering, MBA from IPADE Business School, Executive Programs @ Stanford GSB, Singularity University; Data Science at Galvanize & RNAseq at EcSeq Bioinformatics GmbH (Berlin).

Neil is a Fellow and Lifetime Member of the Institute of Chartered Accountants (ICAEW) and has worked as a professional CFO, for many years, across a broad range of publicly listed and larger privately owned businesses.

He has been working as a Corporate Advisor since 2014, advising a broad range of businesses and NFP’s on strategic planning and development, performance improvement, turnarounds, workouts, managing insolvency situations, litigation support/expert witness, corporate governance, M&A, IPO’s, capital raisings and investor relations.